Deal Dispatch: Amazon Buys Globalstar, Instacart Grabs Instaleap, QVC Announces Bankruptcy

Major M&A deals include: Amazon's $11.6 billion acquisition of Globalstar, OpenAI buys Hiro Finance, and AIP acquires Avanos Medical.

7 Health Care Stocks Whale Activity In Today's Session

Kailera Therapeutics Debut Marks Largest Biotech IPO Since 2021 Amid Weight Loss Race

Kailera Therapeutics prices $625 million IPO, advances GLP-1 obesity pipeline as trial data highlights oral ribupatide weight loss results.

Novo Nordisk Extends Lead As Eli Lilly New Obesity Pill Sees Modest Launch Uptake

Eli Lilly obesity pill logs 1,390 U.S. scripts in first week, trailing Novo's oral Wegovy as competition in weight-loss drugs intensifies.

Reuters Reported 1,390 US Prescriptions For Lilly's Foundayo For Week Ended April 10, Citing IQVIA Data Shared By Analyst

FDA Takes Step Forward on Testosterone Therapy for Men

https://www.fda.gov/news-events/press-announcements/fda-takes-step-forward-testosterone-therapy-men

Eli Lilly Partner MeiraGTx Regains Rights For Genetic Eye Disease Drug From Johnson & Johnson

MeiraGTx reacquires bota-vec from Johnson & Johnson, outlining regulatory plans, funding outlook, and updated xerostomia data.

Eli Lilly's New Oral Weight Loss Drug Clears Cardiovascular Bar

Eli Lilly Foundayo shows cardiovascular safety and stronger A1C, weight reduction, while the FDA flags liver risk, seeks additional data.

Eli Lilly Announces Topline Results From The Phase 3 Achieve-4 Trial Evaluating The Efficacy And Safety Of Foundayo, Which Met The Primary Endpoint By Demonstrating A Non-inferior Risk Of Maj

 In addition, Foundayo showed superior improvements in A1C and body weight at 52 weeks vs. insulin glargine, which persisted through 104 weeks of therapy. While not controlled for multiplicity, the risk of all-cause

GoodRx Rallies As Wegovy HD Rollout Targets Self-Pay Market

GoodRx shares rise as Wegovy HD rollout expands self-pay access, with tiered pricing and mixed technical signals.